ADMA Biologics (ADMA) Receives Daily News Sentiment Score of 0.12

Share on StockTwits

News headlines about ADMA Biologics (NASDAQ:ADMA) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ADMA Biologics earned a news impact score of 0.12 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.630524424331 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of ADMA traded down $0.19 during trading hours on Thursday, reaching $6.66. 5,911 shares of the stock traded hands, compared to its average volume of 219,078. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. ADMA Biologics has a 52-week low of $2.01 and a 52-week high of $6.93. The stock has a market cap of $296.17 million, a price-to-earnings ratio of -3.52 and a beta of 2.35.

A number of equities research analysts have recently issued reports on ADMA shares. Chardan Capital started coverage on shares of ADMA Biologics in a research report on Monday, July 30th. They set a “buy” rating and a $10.00 price objective for the company. Oppenheimer set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Monday, August 13th. BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Maxim Group set a $10.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Monday, May 14th. Finally, ValuEngine raised shares of ADMA Biologics from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Seven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $9.50.

In related news, CEO Adam S. Grossman purchased 52,301 shares of the firm’s stock in a transaction on Friday, June 8th. The shares were acquired at an average price of $4.78 per share, for a total transaction of $249,998.78. Following the purchase, the chief executive officer now directly owns 32,527 shares in the company, valued at $155,479.06. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jerrold B. Grossman bought 20,921 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were acquired at an average price of $4.78 per share, for a total transaction of $100,002.38. Following the completion of the transaction, the director now directly owns 98,007 shares in the company, valued at approximately $468,473.46. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 78,222 shares of company stock worth $373,901. 16.90% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: Diversification in Investing

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply